Silencing of the transcription factor STAT3 sensitizes lung cancer cells to DNA damaging drugs, but not to TNFα- and NK cytotoxicity

Experimental Cell Research

Volumn 319, Issue 4, 2013, Pages 506-516

  Kulesza, Dorota W ^a,b   Carré, Thibault ^c   Chouaib, Salem ^c   Kaminska, Bozena ^a  

^a NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY   (Poland)

^b MEDICAL UNIVERSITY OF WARSAW   (Poland)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

DNA damaging chemotherapeutics; NK cytotoxicity; STAT3 NF B crosstalk; TNF ; Transcription factor STAT3

Indexed keywords

3 (4 METHYLPHENYLSULFONYL) 2 PROPENENITRILE; ANTINEOPLASTIC AGENT; CASPASE 7; CISPLATIN; DOXORUBICIN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN BCL XL; PROTEIN P53; SHORT HAIRPIN RNA; STAT3 PROTEIN; STAT5 PROTEIN; TUMOR NECROSIS FACTOR ALPHA; SMALL INTERFERING RNA; STAT3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE PROGRESSION; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; DNA DAMAGE; FEEDER CELL; GENE SILENCING; HUMAN; HUMAN CELL; LUNG CARCINOMA; NATURAL KILLER CELL; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; REPORTER GENE; UBIQUITINATION; WESTERN BLOTTING; ADOPTIVE IMMUNOTHERAPY; CELL CULTURE; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; EVALUATION; GENE EXPRESSION REGULATION; GENETICS; IMMUNOLOGY; LUNG NON SMALL CELL CANCER; LUNG TUMOR; MULTIMODALITY CANCER THERAPY; PHYSIOLOGY; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DNA DAMAGE; DRUG SYNERGISM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOTHERAPY, ADOPTIVE; KILLER CELLS, NATURAL; LUNG NEOPLASMS; RNA INTERFERENCE; RNA, SMALL INTERFERING; STAT3 TRANSCRIPTION FACTOR; TRANSCRIPTION FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

MLCS; MLOWN;

EID: 84875490171     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2012.11.005     Document Type: Article

References (52)

1. Buettner R., Mora L.B., Jove R. Activated STAT signaling in human tumors provides novel molecular targets for therapeutic intervention. Clin. Cancer Res.: Off. J. Am. Assoc. Cancer Res. 2002, 8:945-954.
2. Haura E.B., Turkson J., Jove R. Mechanisms of disease: insights into the emerging role of signal transducers and activators of transcription in cancer. Nat. Clin. Pract. Oncol. 2005, 2:315-324.
3. Catlett-Falcone R., Landowski T.H., Oshiro M.M., Turkson J., Levitzki A., Savino R., Ciliberto G., Moscinski L., Fernandez-Luna J.L., Nunez G., Dalton W.S., Jove R. Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity 1999, 10:105-115.
4. Bromberg J. Stat proteins and oncogenesis. J. Clin. Invest. 2002, 109:1139-1142.
5. Masuda M., Suzui M., Yasumatu R., Nakashima T., Kuratomi Y., Azuma K., Tomita K., Komiyama S., Weinstein I.B. Constitutive activation of signal transducers and activators of transcription 3 correlates with cyclin D1 overexpression and may provide a novel prognostic marker in head and neck squamous cell carcinoma. Cancer Res. 2002, 62:3351-3355.
6. Karni R., Jove R., Levitzki A. Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene 1999, 18:4654-4662.
7. Aggarwal B.B., Kunnumakkara A.B., Harikumar K.B., Gupta S.R., Tharakan S.T., Koca C., Dey S., Sung B. Signal transducer and activator of transcription-3, inflammation, and cancer: how intimate is the relationship?. Ann. N Y Acad. Sci. 2009, 1171:59-76.
8. Mahboubi K., Li F., Plescia J., Kirkiles-Smith N.C., Mesri M., Du Y., Carroll J.M., Elias J.A., Altieri D.C., Pober J.S. Interleukin-11 up-regulates survivin expression in endothelial cells through a signal transducer and activator of transcription-3 pathway. Lab. Invest.: J. Tech. Methods Pathol. 2001, 81:327-334.
9. Zhao M., Gao F.H., Wang J.Y., Liu F., Yuan H.H., Zhang W.Y., Jiang B. JAK2/STAT3 signaling pathway activation mediates tumor angiogenesis by upregulation of VEGF and bFGF in non-small-cell lung cancer. Lung Cancer 2011, 73:366-374.
10. Wang T., Niu G., Kortylewski M., Burdelya L., Shain K., Zhang S., Bhattacharya R., Gabrilovich D., Heller R., Coppola D., Dalton W., Jove R., Pardoll D., Yu H. Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat. Med. 2004, 10:48-54.
11. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat. Rev. Immunol. 2007, 7:41-51.
12. Gao L., Zhang L., Hu J., Li F., Shao Y., Zhao D., Kalvakolanu D.V., Kopecko D.J., Zhao X., Xu D.Q. Down-regulation of signal transducer and activator of transcription 3 expression using vector-based small interfering RNAs suppresses growth of human prostate tumor in vivo. Clin. Cancer Res. 2005, 11:6333-6341.
13. Huang C., Yang G., Jiang T., Cao J., Huang K.J., Qiu Z.J. Down-regulation of STAT3 expression by vector-based small interfering RNA inhibits pancreatic cancer growth. World J. Gastroenterol.: WJG 2011, 17:2992-3001.
14. Klosek S.K., Nakashiro K., Hara S., Goda H., Hamakawa H. Stat3 as a molecular target in RNA interference-based treatment of oral squamous cell carcinoma. Oncol. Rep. 2008, 20:873-878.
15. Leong P.L., Andrews G.A., Johnson D.E., Dyer K.F., Xi S., Mai J.C., Robbins P.D., Gadiparthi S., Burke N.A., Watkins S.F., Grandis J.R. Targeted inhibition of Stat3 with a decoy oligonucleotide abrogates head and neck cancer cell growth. Proc. Natl. Acad. Sci. USA 2003, 100:4138-4143.
16. Li J., Piao Y.F., Jiang Z., Chen L., Sun H.B. Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice. World J. Gastroenterol.: WJG 2009, 15:2602-2608.
17. Ni Z., Lou W., Leman E.S., Gao A.C. Inhibition of constitutively activated Stat3 signaling pathway suppresses growth of prostate cancer cells. Cancer Res. 2000, 60:1225-1228.
18. Nikitakis N.G., Siavash H., Sauk J.J. Targeting the STAT pathway in head and neck cancer: recent advances and future prospects. Curr. Cancer Drug Targets 2004, 4:637-651.
19. Yue P., Turkson J. Targeting STAT3 in cancer: how successful are we?. Expert Opinion Invest. Drugs 2009, 18:45-56.
20. Zhang X., Zhang J., Wang L., Wei H., Tian Z. Therapeutic effects of STAT3 decoy oligodeoxynucleotide on human lung cancer in xenograft mice. BMC Cancer 2007, 7:149.
21. Bonner J.A., Yang E.S., Trummell H.Q., Nowsheen S., Willey C.D., Raisch K.P. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma. Radiotherapy Oncol.: J. Eur. Soc. Ther. Radiol. Oncol. 2011, 99:339-343.
22. Li X., Wang H., Lu X., Di B. STAT3 blockade with shRNA enhances radiosensitivity in Hep-2 human laryngeal squamous carcinoma cells. Oncol. Rep. 2010, 23:345-353.
23. Haura E.B., Zheng Z., Song L., Cantor A., Bepler G. Activated epidermal growth factor receptor-Stat-3 signaling promotes tumor survival in vivo in non-small cell lung cancer. Clin. Cancer Res. 2005, 11:8288-8294.
24. Kim H.S., Park Y.H., Lee J., Ahn J.S., Kim J., Shim Y.M., Kim J.H., Park K., Han J., Ahn M.J. Clinical impact of phosphorylated signal transducer and activator of transcription 3, epidermal growth factor receptor, p53, and vascular endothelial growth factor receptor 1 expression in resected adenocarcinoma of lung by using tissue microarray. Cancer 2010, 116:676-685.
25. Chouaib S., Meslin F., Thiery J., Mami-Chouaib F. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer. Clin. Immunol. 2009, 130:34-40.
26. Noman M.Z., Buart S., Van Pelt J., Richon C., Hasmim M., Leleu N., Suchorska W.M., Jalil A., Lecluse Y., El Hage F., Giuliani M., Pichon C., Azzarone B., Mazure N., Romero P., Mami-Chouaib F., Chouaib S. The cooperative induction of hypoxia-inducible factor-1 alpha and STAT3 during hypoxia induced an impairment of tumor susceptibility to CTL-mediated cell lysis. J. Immunol. 2009, 182:3510-3521.
27. Ellert-Miklaszewska A., Kaminska B., Konarska L. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell. Signalling 2005, 17:25-37.
28. Chatterjee M., Stuhmer T., Herrmann P., Bommert K., Dorken B., Bargou R.C. Combined disruption of both the MEK/ERK and the IL-6R/STAT3 pathways is required to induce apoptosis of multiple myeloma cells in the presence of bone marrow stromal cells. Blood 2004, 104:3712-3721.
29. Asselin-Paturel C., Megherat S., Vergnon I., Echchakir H., Dorothee G., Blesson S., Gay F., Mami-Chouaib F., Chouaib S. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction. Cancer 2001, 91:113-122.
30. Niu G., Wright K.L., Ma Y., Wright G.M., Huang M., Irby R., Briggs J., Karras J., Cress W.D., Pardoll D., Jove R., Chen J., Yu H. Role of Stat3 in regulating p53 expression and function. Mol. Cell. Biol. 2005, 25:7432-7440.
31. Jin Z., El-Deiry W.S. Overview of cell death signaling pathways. Cancer Biol. Ther. 2005, 4:139-163.
32. Chaturvedi M.M., Sung B., Yadav V.R., Kannappan R., Aggarwal B.B. NF-kappaB addiction and its role in cancer: one size does not fit all. Oncogene 2011, 30:1615-1630.
33. Bromberg J., Darnell J.E. The role of STATs in transcriptional control and their impact on cellular function. Oncogene 2000, 19:2468-2473.
34. Masuda M., Wakasaki T., Suzui M., Toh S., Joe A.K., Weinstein I.B. Stat3 orchestrates tumor development and progression: the Achilles' heel of head and neck cancers?. Curr. Cancer Drug Targets 2010, 10:117-126.
35. Adach-Kilon A., Swiatek-Machado K., Kaminska B., Dabrowski M. Signal transducer and activator of transcription 1 (Stat1) maintains basal mRNA expression of pro-survival stat3-target genes in glioma C6 cells. J. Cell. Biochem. 2011, 112:3685-3694.
36. Nakanishi C., Toi M. Nuclear factor-kappaB inhibitors as sensitizers to anticancer drugs. Nat. Rev. Cancer 2005, 5:297-309.
37. Li F., Sethi G. Targeting transcription factor NF-kappaB to overcome chemoresistance and radioresistance in cancer therapy. Biochim. Biophys. Acta 2010, 1805:167-180.
38. Pandey M.K., Sung B., Kunnumakkara A.B., Sethi G., Chaturvedi M.M., Aggarwal B.B. Berberine modifies cysteine 179 of IkappaBalpha kinase, suppresses nuclear factor-kappaB-regulated antiapoptotic gene products, and potentiates apoptosis. Cancer Res. 2008, 68:5370-5379.
39. Welte T., Zhang S.S., Wang T., Zhang Z., Hesslein D.G., Yin Z., Kano A., Iwamoto Y., Li E., Craft J.E., Bothwell A.L., Fikrig E., Koni P.A., Flavell R.A., Fu X.Y. STAT3 deletion during hematopoiesis causes Crohn's disease-like pathogenesis and lethality: a critical role of STAT3 in innate immunity. Proc. Natl. Acad. Sci. USA 2003, 100:1879-1884.
40. Lee H., Herrmann A., Deng J.H., Kujawski M., Niu G., Li Z., Forman S., Jove R., Pardoll D.M., Yu H. Persistently activated Stat3 maintains constitutive NF-kappaB activity in tumors. Cancer Cell 2009, 15:283-293.
41. Han S.S., Yun H., Son D.J., Tompkins V.S., Peng L., Chung S.T., Kim J.S., Park E.S., Janz S. NF-kappaB/STAT3/PI3K signaling crosstalk in iMyc E mu B lymphoma. Mol. Cancer 2010, 9:97.
42. Quinton L.J., Mizgerd J.P. NF-kappaB and STAT3 signaling hubs for lung innate immunity. Cell Tissue Res. 2011, 343:153-165.
43. Boehm A.L., Sen M., Seethala R., Gooding W.E., Freilino M., Wong S.M., Wang S., Johnson D.E., Grandis J.R. Combined targeting of epidermal growth factor receptor, signal transducer and activator of transcription-3, and Bcl-X(L) enhances antitumor effects in squamous cell carcinoma of the head and neck. Mol. Pharmacol. 2008, 73:1632-1642.
44. Soltani-Arabshahi R., Leboeuf C., Rivet J., Pisonero H., Zhao W.L., Bachelez H., Ameisen J.C., Janin A. Bcl-xL gene expression correlated with lower apoptotic cell numbers and shorter progression-free survival in PCFCL. J. Invest. Dermatol. 2009, 129:1703-1709.
45. Zhao W.L., Daneshpouy M.E., Mounier N., Briere J., Leboeuf C., Plassa L.F., Turpin E., Cayuela J.M., Ameisen J.C., Gisselbrecht C., Janin A. Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma. Blood 2004, 103:695-697.
46. Wang Z.X., Yang J.S., Pan X., Wang J.R., Li J., Yin Y.M., De W. Functional and biological analysis of Bcl-xL expression in human osteosarcoma. Bone 2010, 47:445-454.
47. Karczmarek-Borowska B., Filip A., Wojcierowski J., Smolen A., Korobowicz E., Korszen-Pilecka I., Zdunek M. Estimation of prognostic value of Bcl-xL gene expression in non-small cell lung cancer. Lung Cancer 2006, 51:61-69.
48. Lei X.Y., Zhong M., Feng L.F., Zhu B.Y., Tang S.S., Liao D.F. siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs. Clin. Exp. Pharmacol. Physiol. 2007, 34:450-456.
49. Lei X., Huang Z., Zhong M., Zhu B., Tang S., Liao D. Bcl-XL small interfering RNA sensitizes cisplatin-resistant human lung adenocarcinoma cells. Acta Biochim. Biophys. Sin. 2007, 39:344-350.
50. Shoemaker A.R., Oleksijew A., Bauch J., Belli B.A., Borre T., Bruncko M., Deckwirth T., Frost D.J., Jarvis K., Joseph M.K., Marsh K., McClellan W., Nellans H., Ng S., Nimmer P., O'Connor J.M., Oltersdorf T., Qing W., Shen W., Stavropoulos J., Tahir S.K., Wang B., Warner R., Zhang H., Fesik S.W., Rosenberg S.H., Elmore S.W. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo. Cancer Res. 2006, 66:8731-8739.
51. Verma N.K., Davies A.M., Long A., Kelleher D., Volkov Y. STAT3 knockdown by siRNA induces apoptosis in human cutaneous T-cell lymphoma line Hut78 via downregulation of Bcl-xL. Cell. Mol. Biol. Lett. 2010, 15:342-355.
52. Li S., Wang N., Brodt P. Metastatic cells can escape the pro-apoptotic effects of TNF-alpha through increased autocrine IL-6/STAT3 signalling. Cancer Res. 2011.